Physiomics PLC New Major Pharmaceutical Client (9521C)
January 26 2018 - 2:00AM
UK Regulatory
TIDMPYC
RNS Number : 9521C
Physiomics PLC
26 January 2018
26(th) January 2018
Physiomics plc
("Physiomics") or ("the Company")
New Major Pharmaceutical Client
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is pleased to announce that it has been
awarded a contract by a new major pharmaceutical client. The
project, which is expected to be completed during the Company's
current financial year involves the use of Physiomics' Virtual
Tumour technology in a pre-clinical setting and its value is
approximately GBP35k.
Physiomics' Virtual Tumour is a sophisticated computer model
that simulates tumour cell division and predicts the effect of
different anti-cancer regimes to support pre-clinical and clinical
oncology development programs. Virtual Tumour helps customers to
balance efficacy and toxicity and to prioritise the most effective
drug combinations while reducing time and cost.
Jim Millen, CEO said: "We are delighted to be working with a
significant new client. If this initial project is successful, we
would hope to develop a longer-term relationship."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is a solutions provider to the R&D
based pharmaceutical and biotechnology industry with a focus on
oncology. The Company's Virtual Tumour technology uses computer
modelling to predict the effects of cancer drugs and treatments to
improve the success rate of drug discovery and development projects
while reducing time and cost. The predictive capability of Virtual
Tumour has been confirmed by 55 projects, involving over 25 targets
and 60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Eli Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTXELFLVFFBBBD
(END) Dow Jones Newswires
January 26, 2018 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024